Novo Nordisk filed a lawsuit against Eli Lilly, claiming the rival firm uses outdated clinical data in its advertisements to misrepresent its obesity drugs.

The litigation claims Eli Lilly’s marketing for Mounjaro and Zepbound uses outdated data to unfairly compare efficacy against Wegovy and Ozempic.

Eli Lilly will acquire AtaiBeckley for an upfront equity value of approximately $2.8 billion to gain access to therapies for treatment-resistant depression.